Clinical Services, Specimen Processor
Castle Biosciences
Summary
This position is responsible for performing clinical specimen accessioning, sample sorting, and data entry in a fast-paced, high-throughput environment.
Job description
Evaluates the needs of internal and external clients to provide high-quality customer service. Provide support as needed and defined by those to whom the position reports. Adhere to and ensure compliance with the Company's policies and applicable standard operating procedures.
This role will spend the most time performing data entry login of specimen-related details, accessioning samples into the laboratory information system according to the given protocol with minimal errors and scanning requisitions with all related paperwork, and accurately labeling specimen(s)/slide(s) and ensuring timely distribution to the appropriate areas.
Requirements
- High School diploma or GED equivalent, or equivalent work experience required
- Actively displays behaviors that support the mission, vision, and values of Castle Biosciences required
- Bachelor's Degree or equivalent experience in the laboratory field preferred
- Minimum of 1-year lab accessioning experience preferred
- Previous experience in health care/lab or pharmaceutical industry preferred
- Must be legally authorized to work in the United States
Benefits
- Annual Salary + 20% Bonus Potential
- 20 Accrued PTO Days Annually
- 10 Paid Holidays
- 401K with 100% Company Match up to 6%
- 3 Health Care Plan Options
- Company HSA Contribution
- Company Stock Grant Upon Hire
Company overview
Castle Biosciences (Nasdaq: CSTL) is a leading molecular diagnostics company that develops and commercializes innovative tests to guide patient care decisions. Founded in 2008 and headquartered in Friendswood, Texas, the company focuses primarily on dermatologic and gastroenterological diseases, with a mission to transform disease management through personalized, clinically actionable solutions. Castle's proprietary portfolio includes five commercial tests targeting unmet clinical needs in dermatologic cancers, Barrett's esophagus, and uveal melanoma. Their flagship product, DecisionDx®-Melanoma, is a gene expression profile test that predicts metastasis risk in cutaneous melanoma patients. The company also markets TissueCypher® for Barrett's esophagus, DecisionDx®-SCC for squamous cell carcinoma, MyPath® Melanoma for lesion characterization, and DecisionDx®-UM for uveal melanoma staging. With laboratory operations in Phoenix, Arizona and Pittsburgh, Pennsylvania, Castle Biosciences employs advanced molecular technologies to provide physicians with objective data for more confident treatment planning. The company reported $83 million in Q3 2025 revenue and has demonstrated strong growth in its core testing franchises, positioning itself as a significant player in the precision diagnostics market.